Ranked in Top 6 Global Women’s Health Startups 2024 Report

NZX/ASX Announcement

29 October 2024

TruScreen ranked in Top 6 global women’s Health Startups 2024 report
• StartUs Insights, ranked TruScreen as a Top 6 Startup, as reported in October 2024 ‘6 Top Women’s Health Startups Impacting Healthcare’.
• TruScreen was ranked in the Top 6 picks from a cohort of 580 global women’s healthcare companies evaluated by the StartUs Insights analysts.

StartUs Insights, an Austrian based data science company released its report titled ‘6 Top Women’s Health Startups Impacting Healthcare’. StartUs Insights used AI analytics to evaluate 580 global women’s healthcare companies, ranking TruScreen in its Top 6 Picks.

The report can be found at the link below:
https://www.startus-insights.com/innovators-guide/6-top-womens-health-startups-impacting-healthcare/

The report commented that “Cervical cancer is a major cause of female mortality worldwide, with a bigger death toll in the populations that lack screening programs. Screening methods that don’t require lab facilities for cervical cancer diagnostics can solve the accessibility challenges in developing countries as they are an alternative to traditional Pap smear tests.

TruScreen, based in New Zealand, develops a screening device that detects precancerous changes through optical and electrical measurements of cervical tissue. In a number of studies, https://truscreen.com/product/clinical-performance/, TruScreen proved to be of equal sensitivity compared to Pap tests.

TruScreen can be effectively used with minimal training of medical or paramedical staff and doesn’t require the infrastructure and resource costs associated with cytology-based screening.”

TruScreen CEO Martin Dillon said “The ranking of TruScreen as a global top six women’s healthcare company is a testament of TruScreen’s technology to lower the high global mortality rate of women from Cervical Cancer. TruScreen is pleased to be recognised as a scaled up startup company with technology data sets that are robust and supported with global clinical trials. And that our technology ranks above 574 other global women’s healthcare companies evaluated in 2024 for this report”.

For more information, visit www.truscreen.com or contact:

Martin Dillon
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF